ALMI and Entreprenörsfonden invest in Sprint Bioscience

The company offers a fragment-based drug discovery platform to generate lead compounds faster and at a lower cost compared to traditional high-throughput screening methods. Sprint Bioscience was established in 2009 and is based in Stockholm.

The investment will enable an acceleration of the development of lead compounds for drug discovery used in the healthcare sector.

The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.

If you have any information regarding this transaction, please contact Viktor Lundvall on +44 20 7004 7476 or viktor.lundvall@incisivemedia.com

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Healthcare
• Expansion
• Sweden